Trial Profile
Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- 26 May 2011 New trial record